Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine experience from.pdf (1.72 MB)
Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial
journal contribution
posted on 2023-06-10, 01:39 authored by Farhad Ravandi, Gail J Roboz, Andrew H Wei, Hartmut Döhner, Christopher Pocock, Dominik Selleslag, Pau Montesinos, Hamid Sayar, Maurizio Musso, Angela Figuera-Alvarez, Hana Safah, William Tse, Sang Kyun Sohn, Devendra Hiwase, Timothy ChevassutTimothy Chevassut, Francesca Pierdomenico, Ignazia La Torre, Barry Skikne, Rochelle Bailey, Jianhua Zhong, C L Beach, Herve DombretBackground Most older patients with acute myeloid leukemia (AML) who attain morphologic remission with intensive chemotherapy (IC) will eventually relapse and post-relapse prognosis is dismal. In the pivotal QUAZAR AML-001 trial, oral azacitidine maintenance therapy significantly prolonged overall survival by 9.9 months (P?
History
Publication status
- Published
File Version
- Published version
Journal
Journal of Hematology and OncologyISSN
1756-8722Publisher
BMCExternal DOI
Issue
1Volume
14Page range
1-14Article number
a133Event location
EnglandDepartment affiliated with
- Clinical and Experimental Medicine Publications
Full text available
- Yes
Peer reviewed?
- Yes
Legacy Posted Date
2021-11-08First Open Access (FOA) Date
2021-11-08First Compliant Deposit (FCD) Date
2021-11-05Usage metrics
Categories
No categories selectedLicence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC